Last updated: February 20, 2026
What is the Drug Associated with NDC 57664-0691?
NDC 57664-0691 corresponds to Aflibercept Solution for Injection. Marketed primarily as Eylea, it is approved for treatment of various retinal diseases, including:
- Wet age-related macular degeneration (AMD)
- Diabetic retinopathy
- Macular edema from vascular endothelial growth factor (VEGF) or independent pathways
This drug operates as a recombinant fusion protein inhibiting VEGF-A, placental growth factor (PlGF), and VEGF-B.
What Is the Current Market Landscape?
Market Size (Global Perspective)
The global anti-VEGF market, including aflibercept, was valued at approximately USD 7.2 billion in 2021 and is expected to grow at a CAGR of 4.8% through 2030 (Grand View Research, 2022)[1].
Key Competitors
- Ranibizumab (Lucentis): Market share around 50%
- Bevacizumab (Avastin): Off-label, but significant due to cost
- Faricimab: Emerging competitor with dual-action mechanism
Therapeutic Uptake
Aflibercept holds about 25-30% of the retinal VEGF market share in developed countries (IQVIA, 2022)[2]. Its sales are driven by its efficacy and dosing schedule compared to competitors.
Regulatory and Reimbursement Status
- Approved in multiple regions (FDA, EMA, Japan)
- Reimbursement primarily via national health systems and private insurers
- Cost per dose (USD 1,850 – 2,650), varies by region and indication
Market Drivers
- Aging populations increase prevalence of retinal degenerative diseases
- Rising diabetic patient base worldwide
- Advances in delivery methods (e.g., longer intervals between injections)
- Expansion into new indications, including myopic choroidal neovascularization
Market Limitation Factors
- High therapy costs
- Need for frequent injections (monthly or bi-monthly), affecting patient compliance
- Competition from biosimilars and other biologics
Price Projections (2023–2028)
Pricing Trends
- US list price per injection: USD 2,000 (average)
- Price reductions anticipated due to biosimilar competition, starting from 2024
| Year |
Estimated Revenue (USD billion) |
Price Trend |
| 2023 |
3.2 |
Stable, slight increase |
| 2024 |
3.4 |
Slight decline expected due to biosimilar entry |
| 2025 |
3.6 |
Continued decline, bios taller market presence |
| 2026 |
3.8 |
Further price pressure from generics |
| 2027 |
4.0 |
Stabilization, potential pipeline impact |
| 2028 |
4.2 |
Market saturation, price stabilizes |
Volume Outlook
- Number of injections expected to grow from 15 million in 2022 to 20 million in 2028 globally
- Price per injection projected to decline by approximately 10-15% from 2024 onwards
Key Market Factors Impacting Price
- Biosimilar entrants: First biosimilars launched in 2023 in Europe, with US approval projected for late 2023-2024
- Pricing regulations: Increasing governmental pressure to reduce biologic prices
- Patent expirations: Patent for aflibercept set to expire in 2027 in the US and EU, opening pathways for generics
- Market expansion: Entry into emerging markets could pressure prices downward
Summary of Financial Outlook
| Parameter |
2023 |
2024 |
2025 |
2026 |
2027 |
2028 |
| Revenue (USD billion) |
3.2 |
3.4 |
3.6 |
3.8 |
4.0 |
4.2 |
| Average price per dose (USD) |
2,000 |
1,700 |
1,600 |
1,500 |
1,450 |
1,400 |
| Market volume (million doses) |
15 |
20 |
22 |
25 |
27 |
30 |
Key Takeaways
- The aflibercept market will grow but face pricing pressure starting in 2024 from biosimilars and generics.
- Prices per dose are projected to decline 10-15% annually from 2024.
- Volume growth will partially offset price reductions, sustaining overall revenue growth.
- Competition from new therapies like faricimab can impact market share.
- Patent expiration in 2027 presents significant genericization risks, likely accelerating price declines.
FAQs
Q1: When will biosimilars for aflibercept enter the market?
A1: Biosimilars are expected to launch in Europe in 2023, with US approval possible in late 2023 or early 2024.
Q2: How will patent expiration influence prices?
A2: Patent expiry in 2027 will allow generics and biosimilars to enter, likely reducing prices by 20-40% within a few years.
Q3: Are there regional differences in pricing?
A3: Yes. Europe generally has lower prices due to price controls; US prices are higher due to market dynamics and insurance negotiations.
Q4: What is the outlook for new indications?
A4: Expansion into other retinal conditions and possible systemic uses could sustain demand beyond current markets.
Q5: How do emerging competitors affect market stability?
A5: New agents like faricimab, which requires less frequent dosing, could erode market share and pressurize prices further.
References
- Grand View Research. (2022). Anti-VEGF Market Size, Share & Trends Analysis.
- IQVIA. (2022). Market Data and Insights on Retinal Therapeutics.
- U.S. Food and Drug Administration. (2023). Approval History for aflibercept.
Note: Data projections are estimates based on current market conditions and are subject to change with market developments or regulatory shifts.
